Pantec Biosolutions Receives Clearance for Transdermal Delivery System
Pantec Biosolutions AG (Ruggell, Liechtenstein), a privately owned company developing innovative technologies for transdermal drug delivery, has received CE marking for the company's lead product, P.L.E.A.S.E. (painless laser epidermal system), design which applies micropores into the human skin for the transdermal delivery of large molecular weight drugs.
Pantec Biosolutions AG (Ruggell, Liechtenstein), a privately owned company developing innovative technologies for transdermal drug delivery, has received CE marking for the company's lead product, P.L.E.A.S.E. (painless laser epidermal system), design which applies micropores into the human skin for the transdermal delivery of large molecular weight drugs.
Pantec specializes in using laser microporation technology to deliver large molecular weight drugs into the epidermis for local or systemic uptake. Its proprietary P.L.E.A.S.E. platform enables needle-free and painless administration of biopharmaceutical drugs, in varying and individualized dosages, through partnered patch technology. The technology is currently in clinical trials for the delivery of IVF hormone therapy, a market with an estimated value of $1.5–2 billion.
The rigorous audits required to obtain the CE mark is based on a conformity assessment procedure in which product development and production documentation are thoroughly scrutinized to ensure compliance to the medical device directive. Medical devices are required to bear a CE mark before they can be sold in member countries of the European Economic Area (EEA).
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
